The U.S. Food and Drug Administration (FDA) has approved a once-a-week dose of risedronate (Actonel) for the prevention and treatment of postmenopausal osteoporosis. The new dose became available for prescription in mid-June 2002.
“Actonel 35 mg once-a-week is a valuable new tool for the treatment and prevention of postmenopausal osteoporosis,” Robert Lindsay, MD, PhD, chief of internal medicine at Helen Hayes Hospital, professor of clinical medicine at Columbia University in New York, and principal investigator of the Actonel once-a-week approval study, says in a press release.
Lindsay said that the once-weekly dose is comparable in effectiveness to a daily 5-mg dose.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!